Changzhou Qianhong BiopharmaLTD Future Growth

Future criteria checks 5/6

Changzhou Qianhong BiopharmaLTD is forecast to grow earnings and revenue by 36.6% and 20% per annum respectively. EPS is expected to grow by 37.1% per annum. Return on equity is forecast to be 12.8% in 3 years.

Key information

36.6%

Earnings growth rate

37.1%

EPS growth rate

Pharmaceuticals earnings growth	20.1%
Revenue growth rate	20.0%
Future return on equity	12.8%
Analyst coverage	Low
Last updated	20 Mar 2024

Recent future growth updates

No updates

Recent updates

Does Changzhou Qianhong BiopharmaLTD (SZSE:002550) Have A Healthy Balance Sheet?

Mar 24

Earnings and Revenue Growth Forecasts

SZSE:002550 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	2,729	403	N/A	579	3
12/31/2024	2,308	320	N/A	-56	3
12/31/2023	1,814	182	433	533	N/A
9/30/2023	2,121	253	294	374	N/A
6/30/2023	2,223	241	-18	56	N/A
3/31/2023	2,360	281	-261	-192	N/A
12/31/2022	2,304	323	-142	-71	N/A
9/30/2022	2,155	260	-41	42	N/A
6/30/2022	2,139	294	37	120	N/A
3/31/2022	2,036	255	208	291	N/A
1/1/2022	1,875	181	13	104	N/A
9/30/2021	1,873	-88	23	103	N/A
6/30/2021	1,886	-107	153	231	N/A
3/31/2021	1,913	-52	160	233	N/A
12/31/2020	1,668	-132	255	317	N/A
9/30/2020	1,694	188	154	246	N/A
6/30/2020	1,487	151	58	155	N/A
3/31/2020	1,454	148	-33	70	N/A
12/31/2019	1,675	263	61	162	N/A
9/30/2019	1,462	232	81	196	N/A
6/30/2019	1,490	233	25	137	N/A
3/31/2019	1,350	227	-7	99	N/A
12/31/2018	1,322	221	-78	25	N/A
9/30/2018	1,312	222	-85	-35	N/A
6/30/2018	1,223	202	-8	36	N/A
3/31/2018	1,160	197	45	90	N/A
12/31/2017	1,065	183	4	91	N/A
9/30/2017	995	212	N/A	123	N/A
6/30/2017	931	226	N/A	61	N/A
3/31/2017	863	225	N/A	148	N/A
12/31/2016	776	224	N/A	221	N/A
9/30/2016	773	250	N/A	205	N/A
6/30/2016	788	277	N/A	272	N/A
3/31/2016	750	277	N/A	292	N/A
12/31/2015	757	267	N/A	287	N/A
9/30/2015	730	268	N/A	301	N/A
6/30/2015	744	270	N/A	292	N/A
3/31/2015	771	259	N/A	277	N/A
12/31/2014	815	245	N/A	252	N/A
9/30/2014	807	226	N/A	240	N/A
6/30/2014	791	205	N/A	194	N/A
3/31/2014	832	191	N/A	150	N/A
12/31/2013	861	187	N/A	160	N/A
9/30/2013	907	188	N/A	209	N/A
6/30/2013	847	178	N/A	228	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002550's forecast earnings growth (36.6% per year) is above the savings rate (2.9%).

Earnings vs Market: 002550's earnings (36.6% per year) are forecast to grow faster than the CN market (23.8% per year).

High Growth Earnings: 002550's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 002550's revenue (20% per year) is forecast to grow faster than the CN market (14.4% per year).

High Growth Revenue: 002550's revenue (20% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 002550's Return on Equity is forecast to be low in 3 years time (12.8%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Changzhou Qianhong BiopharmaLTD Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Recent updates

Changzhou Qianhong Biopharma CO.,LTD Proposes Final Cash Dividend for the Year 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Changzhou Qianhong Biopharma CO.,LTD to Report Q1, 2024 Results on Apr 26, 2024

Does Changzhou Qianhong BiopharmaLTD (SZSE:002550) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 17%

High number of new directors

Changzhou Qianhong Biopharma CO.,LTD Approves Board Elections

Changzhou Qianhong Biopharma CO.,LTD to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.026 (vs CN¥0.059 in 2Q 2022)

New major risk - Revenue and earnings growth

Changzhou Qianhong Biopharma CO.,LTD to Report First Half, 2023 Results on Jul 29, 2023

Changzhou Qianhong Biopharma Co.,Ltd Announces Cash Dividend on A Shares for 2022, Payable on May 26, 2023

Full year 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.15 in FY 2021)

Investor sentiment improved over the past week

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.053 (vs CN¥0.081 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.031 in 2Q 2021)

Changzhou Qianhong Biopharma CO.,LTD Announces Final Cash Dividend on A Shares for the Year 2021, Payable on 25 May 2022

Changzhou Qianhong Biopharma Co.,Ltd Approves Dividend for 2021

Investor sentiment improved over the past week

High number of new and inexperienced directors

Changzhou Qianhong Biopharma Co.,Ltd Proposes Distribution for 2021

Third quarter 2021 earnings released: EPS CN¥0.081 (vs CN¥0.066 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.031 (vs CN¥0.074 in 2Q 2020)

Changzhou Qianhong Biopharma Co.,Ltd Announces 2020 Final Distribution Plan to Be Implemented (A Shares), Payable on May 21, 2021

Full year 2020 earnings released: CN¥0.11 loss per share (vs CN¥0.21 profit in FY 2019)

Changzhou Qianhong Biopharma Co., Ltd Announces Executive Elections At the Extraordinary General Meeting Held on January 28, 2021

New 90-day low: CN¥3.89

New 90-day low: CN¥4.22

New 90-day low: CN¥4.32

Third quarter earnings released

New 90-day low: CN¥4.52

First half earnings released

New 90-day high - CN¥4.90

Changzhou Qianhong Biopharma CO.,LTD to Report First Half, 2020 Results on Aug 21, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies